Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer

Phase 2 Completed 41 enrolled National Cancer Institute (NCI)

NaSingle-groupOpen-labelTreatment

Summary

Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Phase II trial to study the effectiveness of lapatinib in treating patients who have recurrent or metastatic prostate cancer.

Timeline

Start: 2004-11
Primary completion: 2007-11
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lapatinib	Small molecule	—	Oral

Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer

Summary

Timeline

Drugs

Indications